Peter A. Thompson
CIK 1357522 · Interim Chief Exec Officer · last filed 2026-07-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.50B
Companies
15
Total Filings
128
Lifetime Open-Market Net
$70.98M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SION | Director | 2,469,959 | $46.55 | $114.98M | -$45.77M | 13 | 2026-07-09 |
| SPRY | Director | 269,323 | $5.67 | $1.53M | -$9.49M | 7 | 2026-06-26 |
| EWTX | Director | 443,792 | $40.35 | $17.91M | $26.74M | 10 | 2026-06-17 |
| CRVS | Director | 8,684,091 | $13.31 | $115.59M | $10.58M | 30 | 2026-06-15 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 0 | $64.97 | $0 | -$25.72M | 14 | 2024-05-20 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Director | 327,852 | $4.91 | $1.61M | $30.00M | 3 | 2022-06-21 |
| JANX | Director | 231,098 | $15.00 | $3.47M | $1.41M | 6 | 2022-06-16 |
| ARS Pharmaceuticals, Inc. (SBTX) Delisted | Director | 952,377 | $5.87 | $5.59M | $25.00M | 4 | 2022-06-13 |
| PMVP | Director | 114,039 | $1.10 | $125.4K | $17.10M | 2 | 2021-06-09 |
| Prevail Therapeutics Inc. (PRVL) Delisted | Director | 12,940,111 | — | — | $15.00M | 2 | 2020-06-19 |
| Synthorx, Inc. (THOR) Delisted | Director | 0 | — | — | $15.00M | 4 | 2020-01-24 |
| ASND | Director | 4,902,910 | $254.44 | $1.25B | $8.09M | 8 | 2018-06-06 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 1,989,949 | — | — | $2.98M | 1 | 2015-07-21 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | — | — | — | $0 | 2 | 2012-05-10 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | President and CEO | 386,419 | — | — | $50.3K | 5 | 2009-08-28 |
Recent Filings · Page 3 of 13
128 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-04-04 | EWTX | Buy (P) | +496,771 | $10.00M | EDGAR |
| 2025-02-10 | SION | Mixed | +3,704,959 | $9.90M | EDGAR |
| 2024-08-28 | SPRY | Sell (S) | −83,695 | -$1.09M | EDGAR |
| 2024-08-23 | SPRY | Sell (S) | −868,682 | -$11.50M | EDGAR |
| 2024-06-24 | SPRY | Grant (A) | — | $0 | EDGAR |
| 2024-06-17 | CRVS | Grant (A) | — | $0 | EDGAR |
| 2024-06-12 | EWTX | Grant (A) | — | $0 | EDGAR |
| 2024-05-20 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Mixed | −2,680,496 | $0 | EDGAR |
| 2024-05-08 | CRVS | Buy (P) | — | $0 | EDGAR |
| 2024-01-25 | EWTX | Buy (P) | +454,545 | $5.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.